Kiss1r Agonist Peptide Programme — Generation 1 Computational Pipeline

An end-to-end agent-driven campaign designing modified kisspeptin decapeptide agonists of KISS1R (GPR54), the obligate receptor for kisspeptin and the primary molecular driver of the hypothalamic-pituitary-gonadal (HPG) axis. Clinical validation precedents: MVT-602 (Myovant / Sumitovant, Phase I/II in fertility) and TAK-683 (Takeda) confirm KISS1R as a druggable target for idiopathic hypogonadotropic hypogonadism (IHH). Generation 1 explored a 10-candidate library (C1-01…C1-10) across a 9-gate pipeline (G0–G9). Two leads advanced: C1-01 (PRODIGY Kd 0.64 nM) and C1-02 (PRODIGY Kd ~140 pM).